European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action
Por:
Luedde, M, Agewall, S, Ambrosio, G, Bayes-Genis, A, Borghi, C, Cerbai, E, Dan, GA, Drexel, H, Ferdinandy, P, Grove, EL, Kaski, JC, Klingenberg, R, Morais, J, Parker, W, Petrie, MC, Rocca, B, Semb, AG, Senni, M, Sohns, C, Sulzgruber, P, Tamargo, J, Metra, M, Böhm, M, Dobrev, D and Sossalla, S
Publicada:
1 nov 2025
Ahead of Print:
1 oct 2025
Resumen:
Heart failure (HF) and atrial fibrillation (AF) are major global health challenges with rising prevalence and significant morbidity, mortality, and healthcare burden. Despite advances in HF management, AF remains a critical comorbidity that worsens outcomes and requires ad hoc treatment strategies, increasing the risk of non-adherence and side effects. While rhythm control strategies in AF have gained attention for their prognostic benefits in HF, the pharmacological treatment of HF in patients with AF, including the benefit of rhythm versus rate control, remains underexplored. The relationship between HF and AF lacks sufficient evidence and targeted research to assess the optimal treatment strategies. This narrative review critically examines current HF pharmacotherapy in the context of AF, focusing on the four cornerstone treatments and modifiers of prognosis for HF with reduced ejection fraction: beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/sacubitril-valsartan, aldosterone antagonists, and sodium-glucose co-transporter 2 inhibitors. Although these therapies are well-established in HF patients, their efficacy in patients with concomitant AF requires further prospective investigation. The unique challenges posed by AF, including arrhythmia-induced remodelling and cardiomyopathy, necessitate a more individually tailored treatment. We also highlight critical knowledge gaps and the need for dedicated clinical trials specifically assessing HF therapies in AF subgroups, such as paroxysmal, long-standing persistent and permanent AF, and the benefit of heart rate and rhythm control strategies. The future of precision medicine in HF-AF management lies in bridging these evidence gaps through targeted research and interdisciplinary collaboration.
Filiaciones:
Luedde, M:
Justus Liebig Univ Giessen, Med Clin 1, Cardiol & Angiol, Klin Str 33, D-35392 Giessen, Germany
Sanecum Grp, Cardiologicum Bremerhaven, Bremerhaven, Germany
Agewall, S:
Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden
Ambrosio, G:
Univ Perugia, Sch Med, Dept Med, Perugia, Italy
Univ Perugia, Sch Med, CERICLET, Perugia, Italy
Inst Cardiovasc Res INRC, Perugia, Italy
:
Hosp Univ Germans Trias i Pujol, Heart Inst, CIBERCV, Badalona, Spain
Borghi, C:
Univ Bologna, Dept Cardiovasc Med, IRCCS AOU S Orsola, Bologna, Italy
Cerbai, E:
Univ Florence, Dept Neurosci, Sect Pharmacol & Toxicol, Florence, Italy
Dan, GA:
Carol Davila Univ Med & Pharm, Acad Romanian Scientists, Bucharest, Romania
Drexel, H:
Vorarlberg Inst Vasc Invest & Treatment VIVIT, Feldkirch, Austria
Ferdinandy, P:
Pharmahungary Grp, Szeged, Hungary
Semmelweis Univ, Ctr Pharmacol & Drug Res & Dev, Budapest, Hungary
Grove, EL:
Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark
Aarhus Univ, Fac Hlth, Dept Clin Med, Aarhus, Denmark
Kaski, JC:
St Georges Univ London, Cardiovasc & Cell Sci Res Inst, London, England
Klingenberg, R:
Justus Liebig Univ Giessen, Med Clin 1, Cardiol & Angiol, Klin Str 33, D-35392 Giessen, Germany
Kerckhoff Clin DZHK, Dept Cardiol, Bad Nauheim, Germany
Stiftung Hosp zum Heiligen Geist, Krankenhaus Nordwest, Frankfurt, Germany
Morais, J:
Polytech Univ Leiria, CiTechCare Ctr Innovat Care & Hlth Technol, Leiria, Portugal
Parker, W:
Univ Sheffield, Cardiovasc Res Unit, Sheffield, England
Petrie, MC:
Univ Glasgow, Sch Cardiovasc & Med Sci, Glasgow, Scotland
Rocca, B:
LUM Univ, Dept Med & Surg, Casamassima, Italy
Semb, AG:
Diakonhjemmet Hosp, REMEDY Ctr, Div Res & Innovat, Prevent Cardiorheuma Clin, Oslo, Norway
Senni, M:
Univ Milano Bicocca, Papa Giovanni XXIII Hosp, Cardiovasc Dept, Bergamo, Italy
Sohns, C:
Ruhr Univ Bochum, Dept Electrophysiol Herz & Diabet Zentrum NRW, Bad Oeynhausen, Germany
Sulzgruber, P:
Med Univ Vienna, Dept Med, Div Cardiol, Vienna, Austria
Tamargo, J:
Univ Complutense, Sch Med, Dept Pharmacol & Toxicol, Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain
Metra, M:
Univ Brescia, Cardiol, Dept Med & Surg Specialties Radiol Sci & Publ Hlth, ASST Spedali Civili, Brescia, Italy
Böhm, M:
Saarland Univ, Univ Klinikum Saarlandes, HOMICAREM HOMburg Inst CArdioREnalMetabol Med, Klin Innere Med 3, Homburg Saar, Germany
Dobrev, D:
Univ Duisburg Essen, Inst Pharmacol, West German Heart & Vasc Ctr, Essen, Germany
Montreal Heart Inst, Dept Med, Montreal, PQ, Canada
Univ Montreal, Montreal, PQ, Canada
Baylor Coll Med, Dept Integrat Physiol, Houston, TX USA
Sossalla, S:
Justus Liebig Univ Giessen, Med Clin 1, Cardiol & Angiol, Klin Str 33, D-35392 Giessen, Germany
Kerckhoff Clin DZHK, Dept Cardiol, Bad Nauheim, Germany
Excellence Cluster Cardiopulm Insitute CPI, Klin Str 33, Giessen, Germany
Green Accepted, Green Submitted, hybrid
|